Goldman Sachs
KRRO icon

Goldman Sachs’s Korro Bio KRRO Stock Holding History

Goldman Sachs’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-364
Closed -$173K – 6377
2021
Q1 		$173K Buy
+364
New +$707K ﹤0.01% 5692

Other funds holding KRRO

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs's KRRO Position: Q1 2026 in Review

Goldman Sachs reduced its Korro Bio (KRRO) stake by 2.7% in Q1 2026, selling an estimated $15.5K and leaving 50,541 shares worth $572K. The position accounts for ﹤0.01% of the portfolio, ranked #5519.

Goldman Sachs first reported a position in KRRO in Q4 2019 and has held it in 20 quarters since. The position peaked at $4.07M in Q1 2024. 99 funds tracked by Wall St. Rank hold KRRO as of Q1 2026.

  • Goldman Sachs held 50,541 shares of Korro Bio worth $572K as of Q1 2026.
  • Goldman Sachs sold 1,409 Korro Bio shares in Q1 2026, an estimated $15.5K.
  • Korro Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5519 holding.
  • Goldman Sachs first reported a position in Korro Bio in Q4 2019 and has held it in 20 quarters since.
  • Goldman Sachs's Korro Bio position peaked at $4.07M in Q1 2024.
  • 99 funds tracked by Wall St. Rank held Korro Bio as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.